title: Improving the effectiveness of (-)-epigallocatechin gallate (EGCG) against rabbit atherosclerosis by EGCG-loaded nanoparticles prepared from chitosan and polyaspartic acid.
abstract: (-)-Epigallocatechin gallate (EGCG) is the major bioactive compound in green tea. Its effect is limited by the harsh environment of the gastrointestinal tract. The present study investigates how the effectiveness of EGCG is influenced by its encapsulation into self-assembled nanoparticles of chitosan (CS) and aspartic acid (PAA). Blank nanoparticles with a mean diameter of ca. 93 nm were prepared from 30-50 kDa PAA and 3-5 kDa CS with a mass rate of 1:1. EGCG was loaded in the nanoparticles to yield EGCG-CS-PAA nanoparticles with an average diameter of 102 nm, which were pH-responsive and demonstrated different EGCG release profiles in simulated gastrointestinal tract media. The average ratio (%) of lipid deposition for EGCG-CS-PAA nanoparticles administered orally to rabbits was 16.9 ± 5.8%, which was close to that of oral simvastatin (15.6 ± 4.1%). Orally administered EGCG alone yielded an average ratio of lipid deposit area of 42.1 ± 4.0%, whereas this value was 65.3 ± 10.8% for the blank nanoparticles. The effectiveness of EGCG against rabbit atherosclerosis was significantly improved by incorporating EGCG into the nanoformulation.
authors.affiliation: Institute of Food Chemistry, Zhejiang A&F University , 88 Huanbei Road, Hangzhou, Zhejiang 311300, China.
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Hong
authors.forename: Yongquan
authors.initials: Y
authors.lastname: Xu
authors.forename: Jun-Feng
authors.initials: JF
authors.lastname: Yin
authors.forename: Jianchang
authors.initials: J
authors.lastname: Jin
authors.forename: Yongwen
authors.initials: Y
authors.lastname: Jiang
authors.forename: Qizhen
authors.initials: Q
authors.lastname: Du
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy*; D001682:Biological Availability; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D048271:Chitosan / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D006801:Humans; D008297:Male; D053758:Nanoparticles / Q000737:chemistry; D010316:Particle Size; D010455:Peptides / Q000737:chemistry*; D011817:Rabbits
chemical_list: D004337:Drug Carriers; D010455:Peptides; C017645:polyaspartate; D002392:Catechin; D048271:Chitosan; C045651:epigallocatechin gallate
keywords: (−)-epigallocatechin gallate; atherosclerosis; effectiveness; nanoparticles